What is HC Wainwright’s Forecast for CGTX Q1 Earnings?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Cognition Therapeutics in a research note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.08) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.07) EPS.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01). During the same quarter in the previous year, the company posted ($0.27) earnings per share.

Several other brokerages have also commented on CGTX. Brookline Capital Management upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. B. Riley raised Cognition Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $1.00 to $1.50 in a research report on Thursday, December 19th. Finally, Chardan Capital dropped their target price on shares of Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $7.50.

Cognition Therapeutics Price Performance

NASDAQ CGTX opened at $0.49 on Tuesday. The stock has a market capitalization of $20.35 million, a PE ratio of -0.50 and a beta of 1.03. Cognition Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.95. The business’s 50-day moving average is $0.58 and its 200 day moving average is $0.55.

Institutional Investors Weigh In On Cognition Therapeutics

A number of large investors have recently added to or reduced their stakes in CGTX. Virtu Financial LLC bought a new stake in shares of Cognition Therapeutics in the third quarter worth $27,000. SG Americas Securities LLC purchased a new position in Cognition Therapeutics in the fourth quarter worth about $26,000. Sigma Planning Corp grew its stake in shares of Cognition Therapeutics by 211.6% during the 4th quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock valued at $431,000 after purchasing an additional 417,300 shares during the period. BIOS Capital Management LP purchased a new stake in shares of Cognition Therapeutics during the 4th quarter valued at about $4,208,000. Finally, Geode Capital Management LLC lifted its stake in shares of Cognition Therapeutics by 8.9% in the 4th quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock worth $247,000 after purchasing an additional 28,705 shares during the period. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.